

## **Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032**

Market Report (7 days) | 2024-02-13 | 180 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

### **Report description:**

Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032

Post Traumatic Stress Disorder (PTSD) Market Outlook

The post-traumatic stress disorder (PTSD) market size is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032 in the major markets, driven by increasing prevalence of post-traumatic stress disorder (PTSD), along with reducing stigma around mental health conditions.

Post Traumatic Stress Disorder (PTSD): Introduction

Post Traumatic Stress Disorder (PTSD) is a mental health condition triggered by experiencing or witnessing a terrifying event. Symptoms include flashbacks, nightmares, severe anxiety, and uncontrollable thoughts about the event. Individuals may also experience emotional numbness and avoidance of situations that remind them of the trauma. PTSD can impair daily functioning and relationships. Treatment often involves psychotherapy, medication, or a combination, aiming to improve symptoms, teach coping strategies, and restore normal functioning.

Key Trends in the Post Traumatic Stress Disorder (PTSD) Market

There's a growing recognition of PTSD beyond traditional contexts like military veterans, encompassing first responders, victims of abuse, and survivors of accidents or natural disasters. This broader understanding is leading to increased diagnosis rates and a higher demand for treatment services.

The market is seeing a shift towards integrated treatment models that combine psychotherapy, medication, and holistic approaches like mindfulness, yoga, and acupuncture. Personalized treatment plans are becoming more common, addressing the individual needs of patients.

Telehealth services, mobile apps, and online therapy platforms are becoming increasingly popular for providing accessible PTSD treatment, especially in remote or underserved areas. Digital platforms also facilitate continuous monitoring and support for individuals with PTSD.

There's a growing emphasis on early intervention and preventive measures in high-risk populations. Programs aimed at education, resilience training, and early trauma counselling are being implemented in various settings, from schools to the military.

The pharmaceutical aspect of the PTSD market is exploring beyond traditional antidepressants. Research into new drug classes and the potential therapeutic use of substances like MDMA and psilocybin for treatment-resistant PTSD is gaining attention.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Increased government funding and supportive regulations for mental health services, including PTSD treatment, are promoting the growth of the market. There's also a trend towards policies that ensure better coverage and access to PTSD therapies under health insurance.

#### Post Traumatic Stress Disorder Market Segmentation

##### Market Breakup by Treatment Type

- Drug Administration

- Psychotherapy

##### Market Breakup by Drug Class

- Antidepressants

- Anti-Anxiety Drugs

- Antipsychotic Drugs

- Others

##### Market Breakup by Patient Type

- Children

- Adult

##### Market Breakup by Distribution Channel

- Hospital Pharmacies

- Retail Pharmacies

- Other Distribution Channels

##### Market Breakup by Region

- United States

- EU-4 and the United Kingdom

- o□Germany

- o□France

- o□Italy

- o□Spain

- o□United Kingdom

- Japan

#### Post Traumatic Stress Disorder (PTSD) Market Overview

In North America, the PTSD market is influenced by a high awareness of mental health issues and robust healthcare infrastructure. The region has a significant number of veterans and active military personnel, leading to focused PTSD research and treatment programs. There's also a growing acceptance of mental health services and an increase in the use of therapy, including cognitive-behavioral therapy and EMDR, coupled with pharmaceutical interventions.

Europe's market is characterized by strong mental health policies and a focus on integrated care. The region benefits from universal healthcare systems, ensuring access to mental health services. There's an emphasis on early intervention and community-based support, with countries like the UK and Germany leading in mental health research and therapy services. The market is also influenced by initiatives aimed at reducing the stigma associated with mental health conditions, including PTSD. The PTSD market in the Japan region is growing, driven by increasing recognition of mental health issues and improving healthcare infrastructure. Cultural factors and stigma associated with mental health can pose challenges. However, there's a gradual shift towards recognizing and treating PTSD, especially in countries with increasing urbanization and changing social dynamics. The market shows potential for growth in therapy services and pharmaceutical treatments, though access to care varies across the region.

#### Post Traumatic Stress Disorder (PTSD) Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

- Sanofi-aventis Groupe

- Emergent BioSolutions Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [ ]Valneva SE
- [ ]GlaxoSmithKline plc.
- [ ]Intervet Inc.
- [ ]EuBiologics Co., Ltd.
- [ ]Astellas Pharma Inc.
- [ ]Celldex Therapeutics.
- [ ]Johnson & Johnson Services Inc.
- [ ]Merck & Co. Inc.
- [ ]Marinus Pharmaceuticals, Inc.
- [ ]Tonix Pharmaceuticals Holding Corp.
- [ ]Greenstone LLC
- [ ]Otsuka Pharmaceutical Co., Ltd
- [ ]Prometheon Pharma, LLC.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

## Table of Contents:

1	Preface
1.1	Objectives of the Study
1.2	Key Assumptions
1.3	Report Coverage - Key Segmentation and Scope
1.4	Research Methodology
2	Executive Summary
3	Post Traumatic Stress Disorder (PTSD) Epidemiology Analysis - 7MM
3.1	7MM Epidemiology Scenario Overview (2017-2032)
3.2	United States Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3	EU-4 and United Kingdom Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.1	Germany Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.2	France Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.3	Italy Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.4	Spain Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.5	United Kingdom Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.4	Japan Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
4	Post Traumatic Stress Disorder (PTSD) Market Overview - 7MM
4.1	Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
4.2	Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032))
5	Post Traumatic Stress Disorder (PTSD) Market Landscape-7MM
5.1	Post Traumatic Stress Disorder (PTSD) Developers Landscape
5.1.1	Analysis by Year of Establishment
5.1.2	Analysis by Company Size
5.1.3	Analysis by Region
5.2	Post Traumatic Stress Disorder (PTSD) Product Landscape
5.2.1	Analysis by Diseases Type
5.2.2	Analysis by Treatments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.2.3 Analysis by Route of Administration
- 6 Post Traumatic Stress Disorder (PTSD) Treatment Challenges and Unmet Needs
  - 6.1 Treatment Pathway Challenges
  - 6.2 Compliance and Drop-Out Analysis
  - 6.3 Awareness and Prevention Gaps
- 7 Cost of Treatment
- 8 Post Traumatic Stress Disorder (PTSD) Market Dynamics
  - 8.1 Market Drivers and Constraints
  - 8.2 SWOT Analysis
  - 8.3 Porter's Five Forces Model
  - 8.4 Key Demand Indicators
  - 8.5 Key Price Indicators
  - 8.6 Industry Events, Initiatives, and Trends
  - 8.7 Value Chain Analysis
- 9 Post Traumatic Stress Disorder (PTSD) Market Segmentation -7MM
  - 9.1 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
    - 9.1.1 Market Overview
    - 9.1.2 Drug Administration
    - 9.1.3 Psychotherapy
  - 9.2 Post Traumatic Stress Disorder (PTSD) Market by Drug Class
    - 9.2.1 Market Overview
    - 9.2.2 Antidepressants
    - 9.2.3 Anti-Anxiety Drugs
    - 9.2.4 Antipsychotic Drugs
    - 9.2.5 Others
  - 9.3 Post Traumatic Stress Disorder (PTSD) Market by Patient Type
    - 9.3.1 Market Overview
    - 9.3.2 Children
    - 9.3.3 Adult
  - 9.4 Post Traumatic Stress Disorder (PTSD) Market by Distribution Channel
    - 9.4.1 Market Overview
    - 9.4.2 Hospital Pharmacies
    - 9.4.3 Retail Pharmacies
    - 9.4.4 Other Distribution Channels
  - 9.5 Post Traumatic Stress Disorder (PTSD) Market by Region
    - 9.5.1 Market Overview
    - 9.5.2 United States
    - 9.5.3 EU-4 and the United Kingdom
      - 9.5.3.1 Germany
      - 9.5.3.2 France
      - 9.5.3.3 Italy
      - 9.5.3.4 Spain
      - 9.5.3.5 United Kingdom
    - 9.5.4 Japan
- 10 United States Post Traumatic Stress Disorder (PTSD) Market
  - 10.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
  - 10.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.3 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
- 10.4 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
- 11 EU-4 and United Kingdom Post Traumatic Stress Disorder (PTSD) Market
  - 11.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
  - 11.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
  - 11.3 Germany Post Traumatic Stress Disorder (PTSD) Market Overview
    - 11.3.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
    - 11.3.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
  - 11.4 France Post Traumatic Stress Disorder (PTSD) Market Overview
    - 11.4.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
    - 11.4.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
  - 11.5 Italy Post Traumatic Stress Disorder (PTSD) Market Overview
    - 11.5.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
    - 11.5.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
  - 11.6 Spain Post Traumatic Stress Disorder (PTSD) Market Overview
    - 11.6.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
    - 11.6.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
  - 11.7 United Kingdom Post Traumatic Stress Disorder (PTSD) Market Overview
    - 11.7.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
    - 11.7.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
- 12 Japan Post Traumatic Stress Disorder (PTSD) Market
  - 12.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
  - 12.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
    - 12.2.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
    - 12.2.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
- 13 Regulatory Framework
  - 13.1 Regulatory Overview
  - 13.2 US FDA
  - 13.3 EU EMA
  - 13.4 INDIA CDSCO
  - 13.5 JAPAN PMDA
  - 13.6 Others
- 14 Patent Analysis
  - 14.1 Analysis by Type of Patent
  - 14.2 Analysis by Publication year
  - 14.3 Analysis by Issuing Authority
  - 14.4 Analysis by Patent Age
  - 14.5 Analysis by CPC Analysis
  - 14.6 Analysis by Patent Valuation
  - 14.7 Analysis by Key Players
- 15 Grants Analysis
  - 15.1 Analysis by year
  - 15.2 Analysis by Amount Awarded
  - 15.3 Analysis by Issuing Authority
  - 15.4 Analysis by Grant Application
  - 15.5 Analysis by Funding Institute
  - 15.6 Analysis by NIH Departments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.7 Analysis by Recipient Organization
- 16 Clinical Trials Analysis
  - 16.1 Analysis by Trial Registration Year
  - 16.2 Analysis by Trial Status
  - 16.3 Analysis by Trial Phase
  - 16.4 Analysis by Therapeutic Area
  - 16.5 Analysis by Geography
- 17 Funding and Investment Analysis
  - 17.1 Analysis by Funding Instances
  - 17.2 Analysis by Type of Funding
  - 17.3 Analysis by Funding Amount
  - 17.4 Analysis by Leading Players
  - 17.5 Analysis by Leading Investors
  - 17.6 Analysis by Geography
- 18 Partnership and Collaborations Analysis
  - 18.1 Analysis by Partnership Instances
  - 18.2 Analysis by Type of Partnership
  - 18.3 Analysis by Leading Players
  - 18.4 Analysis by Geography
- 19 Supplier Landscape
  - 19.1 Sanofi-aventis Groupe
    - 19.1.1 Financial Analysis
    - 19.1.2 Product Portfolio
    - 19.1.3 Demographic Reach and Achievements
    - 19.1.4 Mergers and Acquisitions
    - 19.1.5 Certifications
  - 19.2 Emergent BioSolutions Inc.
    - 19.2.1 Financial Analysis
    - 19.2.2 Product Portfolio
    - 19.2.3 Demographic Reach and Achievements
    - 19.2.4 Mergers and Acquisitions
    - 19.2.5 Certifications
  - 19.3 Valneva SE
    - 19.3.1 Financial Analysis
    - 19.3.2 Product Portfolio
    - 19.3.3 Demographic Reach and Achievements
    - 19.3.4 Mergers and Acquisitions
    - 19.3.5 Certifications
  - 19.4 GlaxoSmithKline plc.
    - 19.4.1 Financial Analysis
    - 19.4.2 Product Portfolio
    - 19.4.3 Demographic Reach and Achievements
    - 19.4.4 Mergers and Acquisitions
    - 19.4.5 Certifications
  - 19.5 Intervet Inc.
    - 19.5.1 Financial Analysis
    - 19.5.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Mergers and Acquisitions
- 19.5.5 Certifications
- 19.6 EuBiologics Co., Ltd.
  - 19.6.1 Financial Analysis
  - 19.6.2 Product Portfolio
  - 19.6.3 Demographic Reach and Achievements
  - 19.6.4 Mergers and Acquisitions
  - 19.6.5 Certifications
- 19.7 Astellas Pharma Inc.
  - 19.7.1 Financial Analysis
  - 19.7.2 Product Portfolio
  - 19.7.3 Demographic Reach and Achievements
  - 19.7.4 Mergers and Acquisitions
  - 19.7.5 Certifications
- 19.8 Celldex Therapeutics.
  - 19.8.1 Financial Analysis
  - 19.8.2 Product Portfolio
  - 19.8.3 Demographic Reach and Achievements
  - 19.8.4 Mergers and Acquisitions
  - 19.8.5 Certifications
- 19.9 Johnson & Johnson Services Inc.
  - 19.9.1 Financial Analysis
  - 19.9.2 Product Portfolio
  - 19.9.3 Demographic Reach and Achievements
  - 19.9.4 Mergers and Acquisitions
  - 19.9.5 Certifications
- 19.10 Merck & Co. Inc.
  - 19.10.1 Financial Analysis
  - 19.10.2 Product Portfolio
  - 19.10.3 Demographic Reach and Achievements
  - 19.10.4 Mergers and Acquisitions
  - 19.10.5 Certifications
- 19.11 Marinus Pharmaceuticals, Inc.
  - 19.11.1 Financial Analysis
  - 19.11.2 Product Portfolio
  - 19.11.3 Demographic Reach and Achievements
  - 19.11.4 Mergers and Acquisitions
  - 19.11.5 Certifications
- 19.12 Tonix Pharmaceuticals Holding Corp.
  - 19.12.1 Financial Analysis
  - 19.12.2 Product Portfolio
  - 19.12.3 Demographic Reach and Achievements
  - 19.12.4 Mergers and Acquisitions
  - 19.12.5 Certifications
- 19.13 Greenstone LLC
  - 19.13.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 19.13.2 Product Portfolio
- 19.13.3 Demographic Reach and Achievements
- 19.13.4 Mergers and Acquisitions
- 19.13.5 Certifications
- 19.14 Otsuka Pharmaceutical Co., Ltd
  - 19.14.1 Financial Analysis
  - 19.14.2 Product Portfolio
  - 19.14.3 Demographic Reach and Achievements
  - 19.14.4 Mergers and Acquisitions
  - 19.14.5 Certifications
- 19.15 Prometheon Pharma, LLC.
  - 19.15.1 Financial Analysis
  - 19.15.2 Product Portfolio
  - 19.15.3 Demographic Reach and Achievements
  - 19.15.4 Mergers and Acquisitions
  - 19.15.5 Certifications
- 20 Post Traumatic Stress Disorder (PTSD) - Distribution Model (Additional Insight)
  - 20.1 Overview
  - 20.2 Potential Distributors
  - 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 22 Company Competitiveness Analysis (Additional Insight)
  - 22.1 Very Small Companies
  - 22.2 Small Companies
  - 22.3 Mid-Sized Companies
  - 22.4 Large Companies
  - 22.5 Very Large Companies
- 23 Payment Methods (Additional Insight)
  - 23.1 Government Funded
  - 23.2 Private Insurance
  - 23.3 Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.



## Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-13 | 180 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$5499.00
	Five User License	\$7499.00
	Corporate License	\$9499.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-03"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com